CA7

Carbonic anhydrase 7 · P43166 · CA7 on Sugi Atlas →

443,358 patent compounds predicted against CA7, 263,228 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL17986	1.00	13/20
Benzthiazide (SCHEMBL26257)	0.42	9/20
SCHEMBL19880	0.55	8/20
Sulfanilamide (SCHEMBL740)	1.00	7/20
Coumarin (SCHEMBL6252)	1.00	7/20
SCHEMBL8588	0.43	7/20
SCHEMBL16810	0.42	7/20
Benzthiazide (SCHEMBL26258)	0.42	7/20
SCHEMBL19256	0.34	7/20
SCHEMBL19257	0.34	7/20
Benzenesulfonamide (SCHEMBL729)	1.00	5/20
Methylparaben (SCHEMBL4440)	1.00	5/20
Spermine (SCHEMBL14965)	1.00	5/20
Trientine (SCHEMBL15439)	1.00	5/20
Spermidine (SCHEMBL15618)	1.00	5/20
SCHEMBL15797	1.00	5/20
Tiliroside (SCHEMBL23597)	1.00	5/20
Tiliroside (SCHEMBL23598)	1.00	5/20
SCHEMBL26707	1.00	5/20
SCHEMBL20976	0.86	5/20

Clinical trials — most relevant to CA7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Multicenter Trial of Antithrombotic Strategies in Acute Coronary Syndrome With Coronary Artery Ectasia	PHASE4	RECRUITING
Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer	PHASE3	COMPLETED
A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease	PHASE2/PHASE3	COMPLETED
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer	PHASE2	COMPLETED
Vitamin D Dose-Response Study to Establish Dietary Requirements in Infants	PHASE2	COMPLETED
Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model	PHASE1/PHASE2	UNKNOWN
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer	PHASE1	COMPLETED
Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers	PHASE1	COMPLETED
Study of 177Lu-PSMA-0057 in Metastatic Prostate Cancer	EARLY_PHASE1	UNKNOWN
The Etiology and Progression of Brain Tumors	nan	COMPLETED
Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma	nan	RECRUITING
Cultured Circulating Tumor Cells in Prostate and Other Cancers	nan	UNKNOWN
Selecting Hypoxic Tumours for Treatment Modification	nan	RECRUITING
Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma	nan	RECRUITING
Tumor Specific Plasma DNA	nan	COMPLETED
A Longitudinal Study to Analyse the Correlation Between CAI and Bilirubin	nan	UNKNOWN
Implication of Long Non-coding RNA CCDC144NL-AS1/Micro RNA-143-3p Axis Expression Level as Novel Signature in Colorectal Cancer	nan	COMPLETED
Urine Cadmium Levels in Predicting Pancreatic Cancer Risk in Patients With Chronic Pancreatitis	nan	COMPLETED
Improving Safety in Pediatric Thyroidectomy by PTH Measurements	nan	COMPLETED
Sialic Acid in Hepatocellular Carcinoma	nan	NOT_YET_RECRUITING
Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma.	nan	COMPLETED
89Zr-DFO-girentuximab Expanded Access Program (EAP)	nan	NO_LONGER_AVAILABLE
Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines	nan	UNKNOWN
Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease	nan	COMPLETED
A Pilot Study of a Protein Profile Test in Ovarian Cancer Patients in Remission to See if Protein Changes Can Predict Relapse (be Predictive of Cancer Relapse)	nan	COMPLETED
Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer	nan	RECRUITING
Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer	nan	COMPLETED
Head-to-head Comparison of Positron Nuclide Radio-labeled FAPI and 18F-FDG PET/CT in Patients With Malignant Tumors	nan	UNKNOWN
Mucin Glycosylating Enzymes in Head and Neck Cancers	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CA7 binder may also engage these)

Protein	Name	Similarity
Q9ERQ8	—	1.000	Q9ERQ8 →
Q9D6N1	—	0.997	Q9D6N1 →
CA3	Carbonic anhydrase 3	0.997	landscape →
CA13	Carbonic anhydrase 13	0.992	landscape →
P07630	—	0.992	P07630 →
P27139	—	0.990	P27139 →
Q5S1S4	—	0.988	Q5S1S4 →
P07450	—	0.988	P07450 →
Q3SZX4	—	0.987	Q3SZX4 →
P16015	—	0.987	P16015 →
CA2	Carbonic anhydrase 2	0.986	landscape →
P48282	—	0.984	P48282 →
P00920	—	0.984	P00920 →
Q8UWA5	—	0.984	Q8UWA5 →
P14141	—	0.984	P14141 →
P00921	—	0.982	P00921 →
Q92051	—	0.982	Q92051 →
P00919	—	0.982	P00919 →
P35217	—	0.980	P35217 →
P00916	—	0.979	P00916 →
Q8HY33	—	0.979	Q8HY33 →
P00922	—	0.977	P00922 →
P83299	—	0.977	P83299 →
P13634	—	0.977	P13634 →
P07452	—	0.977	P07452 →
Q1LZA1	—	0.976	Q1LZA1 →
B0BNN3	—	0.972	B0BNN3 →
Q7M316	—	0.971	Q7M316 →
P00917	—	0.971	P00917 →
CA1	Carbonic anhydrase 1	0.970	landscape →